

Arrivo BioVentures to Participate in Piper Sandler Virtual CNS Symposium

MORRISVILLE, N.C., August 14, 2025 – [Arrivo BioVentures](#) today announced that management will participate in a virtual fireside chat at the Piper Sandler Virtual CNS Symposium on August 14, 2025.

Fireside Chat Details:

- **Date:** Thursday, August 14, 2025
- **Time:** 10:30-10:55am ET
- **Participants:** Steve Butts, Co-founder and Chief Executive Officer, and Joel Raskin, MD, Chief Medical Officer

This virtual event is invitation-only, exclusive to Piper Sandler clients. For additional details or to request access to the webcast, please contact your Piper Sandler representative.

For more about Arrivo and Forvisirvat, visit www.arrivobio.com.

About Arrivo BioVentures

Arrivo is developing first-of-its-kind medicines that target the root cause of hard-to-treat diseases with the goal of achieving meaningful outcomes for patients, allowing them to live longer, healthier lives. Arrivo has two clinical-stage pipeline candidates, Forvisirvat (SP-624) for major depressive disorder and RABI-767 for predicted severe acute pancreatitis. Arrivo is based in Morrisville, N.C., on the edge of Research Triangle Park. For more information, visit www.arrivobio.com.

Media Contact:

Alexis Feinberg

Vice President, ICR Healthcare

Alexis.feinberg@icrhealthcare.com